US Food and Drug Administration FDA public health advisory: updated safety information about Raptiva (efalizumab) [online] (2009). US Food and Drug Administration FDA approves updated labeling for ...

This may be the last straw for Raptiva (efalizumab), a monoclonal antibody (mAb) directed against T-cell marker CD-11. “It's doomed,” says Eric Schmidt, biotech analyst with Cowen and Company ...

Efalizumab (Raptiva ™) is a representative example of a biologic agent, for which two large phase III trials have recently been completed. It is a targeted T-cell modulator that inhibits ...

Fortunately, many recent case reports as well as a recent phase IV study suggest that the biologic agent efalizumab (Raptiva ®) may be effective in treating psoriasis of the hands and/or feet ...